Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367685 | 1.00 | GAA (0.55) | GAACRBNDDB1IKZF3 | |
| SCHEMBL31068584 | 0.91 | GAA (0.52) | GAACRBNDDB1IKZF3 | |
| SCHEMBL23513495 | 0.86 | GAA (0.59) | GAACRBNDDB1 | |
| SCHEMBL14277693 | 0.86 | GAA (0.59) | GAACRBNDDB1 | |
| SCHEMBL4760856 | 0.86 | GAA (0.59) | GAACRBNDDB1 | |
| SCHEMBL19370828 | 0.83 | CRBN (0.47) | GAACRBNDDB1IKZF3 | |
| SCHEMBL19370827 | 0.83 | CRBN (0.47) | GAACRBNDDB1IKZF3 | |
| SCHEMBL27022473 | 0.83 | GAA (0.50) | GAACRBNDDB1 | |
| SCHEMBL14133861 | 0.82 | GAA (0.46) | GAACRBNDDB1 | |
| SCHEMBL24873296 | 0.82 | BTK (0.51) | GAACRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| CN-1867331-B | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2010-05-26 | — | — | CN | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GAA 1234/4885CRBN 187/4885DDB1 1267/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | GAA 1360/4885CRBN 321/4885DDB1 953/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GAA 1234/4885CRBN 187/4885DDB1 1267/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | GAA 694/4885CRBN 4327/4885DDB1 3430/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | GAA 3366/4885CRBN 1/4885DDB1 2979/4885 |
| US-20240368179-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE | CRBN, MDM2, UBE2N | GAA 663/4885CRBN 1/4885DDB1 468/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | GAA 2087/4885CRBN 3/4885DDB1 1156/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | GAA 4574/4885CRBN 938/4885DDB1 1951/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GAA 1234/4885CRBN 187/4885DDB1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.